Prostate ...

[BBC3]

Thats interesting, because last time I checked, IT VIRTUALLY IMPOSSIBLE to get TT levels that high. The blood simply will not hold it, or recognize it in serum if not trained to by recent activity/demand. Which would mean someone has to have trained massive amounts of muscle mass or have large estrogen demands in place. I KNEW a guy who once supplemented 100mgs test cyp a week and could not get levels over 2100ng/dl. He was only moderately trained and not that fat......

[This IS NOT a typo! The research calls for testosterone use in PrCa. Moreover, at levels of 2500-3500 ng/dL, which is north of 200 mg/week.]

Androgens As Therapy For Androgen Receptor Positive Castration Resistant Prostate Cancer

Based on the results from the researchers’ model, patients developing relapsed hormone-refractory prostate tumors after androgen ablation therapy should be biopsied for expression level of Androgen Receptor (AR) protein in tumors. Intermittent Androgen Deprivation (IAD) and/or administration of exogenous androgen at a concentration 2500-3500 ng/dl will benefit patients with AR-rich relapsed tumors by suppressing tumor growth, improving quality of life, and reducing risks for cardiovascular diseases and diabetes. Combined treatment of androgen ablation therapy with anti-androgen causes a rapid and irreversible selection of more aggressive advanced prostate cancer cells. Exogenous androgen treatment can cause regression of these tumors and a subgroup of these tumors will disappear.

Androgen deprivation therapy alone may promote a slow adaptation to androgen ablation-resistance, thus shortening the period of androgen deprivation therapy may retard the diseases progression and reduce side effects. Aromatase inhibitors should be considered in combination with androgen treatment to prevent the conversion of testosterone to estradiol (E2) by aromatase to avoid potential cardiac toxicity. Since several clinical trials already confirmed that testosterone is a safe, feasible, and reasonably well-tolerated therapy for men with early hormone-refractory prostate cancer, we believe that manipulating androgen/AR signaling can be a potential therapy for AR-positive advanced prostate cancer.


Chuu CP, Kokontis JM, Hiipakka RA, et al. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 2011;18:63. Journal of Biomedical Science | Full text | Androgens as Therapy for Androgen Receptor-Positive Castration-Resistant Prostate Cancer

Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men in Western countries. While surgery is often successful for organ-confined prostate cancer, androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, this therapy is associated with several undesired side-effects, including increased risk of cardiovascular diseases. Shortening the period of androgen ablation therapy may benefit prostate cancer patients. Intermittent Androgen Deprivation therapy improves quality of life, reduces toxicity and medical costs, and delays disease progression in some patients.

Cell culture and xenograft studies using androgen receptor (AR)-positive castration-resistant human prostate cancers cells (LNCaP, ARCaP, and PC-3 cells over-expressing AR) suggest that androgens may suppress the growth of AR-rich prostate cancer cells. Androgens cause growth inhibition and G1 cell cycle arrest in these cells by regulating c-Myc, Skp2, and p27Kip via AR. Higher dosages of testosterone cause greater growth inhibition of relapsed tumors. Manipulating androgen/AR signaling may therefore be a potential therapy for AR-positive advanced prostate cancer.

 

[BBC3]

With regard to all the diet pills the FDA has identified as containing questionable ingredients:

[ame=http://en.wikipedia.org/wiki/Sibutramine]Sibutramine - Wikipedia, the free encyclopedia[/ame]

Sibutramine seems to be the primary ingredient of concern. Very interesting all the Serotoinin, NE, and DOP activity associated...!

 

[BBC3]

My first thoughts on a potential debunk of this study would be, sure = low tt, but as a result of what?

Low TT in response to heavy estrogen and fat or sedentary behavior patterns, or low tt as general testicular TRUE type 1 or 2 failure!?!? (OR are they all in fact the same anyway!?!?!?)

So we still beat around the bush as to the relationship of estrogen with regard to PC, and again I note the failure of Serum COUNTING....

Botto H, Neuzillet Y, Lebret T, Camparo P, Molinie V, Raynaud JP. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol 2011;186(4):1400-5. Elsevier

PURPOSE: We characterized the aggressiveness of prostate cancer by Gleason score and predominant Gleason pattern in relation to preoperative serum testosterone.

MATERIALS AND METHODS: In a prospective study serum total testosterone was measured preoperatively in patients referred to our department from January 2007 to January 2011 for radical prostatectomy. Gleason score and predominant Gleason pattern were determined in prostate biopsy and prostate tissue specimens.

RESULTS: A total of 431 patients were enrolled in the study. In biopsies a predominant Gleason pattern 4 was observed in 72 patients (17%). In prostate specimens the predominant Gleason pattern 4 increased to 132 patients (31%). In the 132 patients total testosterone was lower than in the 299 with predominant Gleason pattern 3 (4.00 vs 4.50 ng/ml, p = 0.001), prostate specific antigen was higher (8.4 vs 6.6 ng/ml, p <0.00001), and extraprostatic extension and positive margins were noted more often (49% vs 20% and 23% vs 14%, p <0.000001 and 0.02, respectively). The 62 patients with total testosterone less than 3.0 ng/ml were larger (mean 7 kg, p = 0.0001) with a higher body mass index (mean 0.5 kg/m(2), p <0.000001). They had a higher percent of Gleason score with predominant Gleason pattern 4 (47% vs 28%, p = 0.002).

CONCLUSIONS: Low total testosterone is associated with a higher percent of predominant Gleason pattern 4, a signature of prostate cancer aggressiveness. Tumor aggressiveness cannot be accurately estimated by biopsy Gleason score and predominant Gleason pattern. Preoperative total testosterone should be added to prostate specific antigen determination to improve management for prostate cancer.

 

[Michael Scally MD]

Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol 2011;8(3):123-4. http://www.nature.com/nrurol/journal/v8/n3/pdf/nrurol.2011.10.pdf

The potential of the prostate cancer antigen 3 (PCA3) urine assay to aid prostate cancer diagnosis and minimize unnecessary biopsies has been extensively studied. Results from three recent studies that compared the performance of PCA3 with PSA underscore the advancement and future challenges for this new diagnostic biomarker.

Declaration: S. Srivastava has received grant/research support from Gen-Probe.

 

[Michael Scally MD]

FDA Approves Gen-Probe's PROGENSA® PCA3 Assay, First Urine-Based Molecular Test to Help Determine Need for Repeat Prostate Biopsies
http://www.gen-probe.com/news/PressReleaseText.asp?releaseID=1661248

- Test May Help Reduce Unnecessary Repeat Prostate Biopsies --

SAN DIEGO, Feb. 15, 2012 /PRNewswire/ -- Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

Gen-Probe Incorporated (NASDAQ:GPRO) http://www.gen-probe.com/
GF: Gen-Probe Incorporated: NASDAQ:GPRO quotes & news - Google Finance

 

[Michael Scally MD]

Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort—Results from the Canary/EDRN Prostate Active Surveillance Study.
Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort—Results from the Canary/EDRN Prostate Active Surveillance Study. - ASCO

 

[Michael Scally MD]

Special Section on the Complications of Androgen Deprivation Therapy
http://www.nature.com/aja/journal/v14/n2/index.html?WT.ec_id=AJA-201203

Note: There are many similarities between AIH and ADT.

 

[Michael Scally MD]

May KF, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate Cancer Immunotherapy. Clinical Cancer Research 2011;17(16):5233-8. Prostate Cancer Immunotherapy

The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.

 

[Michael Scally MD]

Prostate Cancers Detected During 5alpha Reductase Inhibitor Use

Treatment of benign prostatic hyperplasia (BPH) with 5?-reductase inhibitors (5?RI) is now widespread. The 5?RI drugs block the conversion of testosterone into the more active dihydrotestosterone, leading to shrinkage of androgen sensitive tissues in the prostate. Besides the use for treatment of BPH, the anti-androgenic effects of 5?RI have been extensively explored for the chemoprevention of prostate cancer. In the largest studies to date, both finasteride and dutasteride were associated with a decrease in the overall number of prostate cancer cases. However, an unexpected finding was an increase in the rate of high grade cancer detected in the 5?RI groups compared to controls and raises questions about a possible association between 5?RI and biologically aggressive tumors.

Multiple studies have demonstrated a strong association between prostate cancer size, pathologic grade and curability. Before the era of 5?RI drugs, most tumors < 1 cm in size were of low Gleason grade, confined to the prostate, and considered “curable”. Small tumors with high Gleason grades and aggressive biologic behaviors were unusual. The motivation for this study was the recent anecdotal observation in our practice of an unexpected number of small prostate cancers with high Gleason grades in men treated with 5?RI drugs. Therefore, the purpose of this study was to retrospectively compare the characteristics of size matched cancers in patients treated with 5?RI vs. a control group consisting of cancers in untreated patients.

The randomized controlled trials investigating the potential chemopreventive attributes of 5?RI drugs published to date were designed primarily to detect a difference in the incidence of prostate cancer in a large population treated with 5?RI drugs. As a result, routine biopsies performed at fixed time intervals (without a particular clinical indication) were a critical component of the trial design. The results of these timed biopsies demonstrated a decrease in the overall number of cancers detected in 5?RI-treated subjects compared to untreated controls. This decreased number of detected cancers led the authors to conclude that 5?RI drugs were chemopreventive against prostate cancer. By way of contrast, this study is a retrospective analysis of a series of prostatic biopsies performed for specific clinical indications (an abnormal physical examination, rising or abnormal PSA, or a hypoechoic lesion detected at ultrasound), i.e. “for cause.” Therefore, the focus of the study is on those patients that already have met the criteria to undergo prostatic biopsy, not an epidemiologic study of the effect of 5?RI treatment on a population. In this setting, the positive biopsy rate was slightly higher for patients treated with 5?RI when compared to controls (76% vs. 58%, p=0.04). They believe that biopsying “for cause” such as in this study, is representative of most clinical practices, and is best used to inform physicians and patients when management decisions are being made. Interestingly, in the two randomized studies of 5?RI for chemoprevention of prostate cancer published to date (PCPT and REDUCE), biopsies performed "for cause” found no significant difference in prostate cancer detection rates between groups.


Lee F, Badalament RA, Hu C, Bousho I, Tsodikov A. Prostate cancers detected during 5alpha-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls. J Cancer 2012;3:122-8. http://www.jcancer.org/v03p0122.pdf

Rationale: To compare cancers detected during use of 5alpha-reductase inhibitors (5alphaRI) with cancers detected in untreated controls stratified for tumor size.

Methods: Prostate biopsies were performed on 235 consecutive patients "for cause" (elevated or rising PSA, positive digital rectal examination, or focal hypoechoic lesion). Fifty patients were excluded for a prior diagnosis of cancer, leaving 185 as the study group (5alphaRI=41, control=144). Patients in the 5alphaRI group had been treated for a mean of 3.5 years. Cancer was ultimately diagnosed in 114/185 patients.

Results: Cancer was diagnosed in 31/41 (76%) of patients treated with 5alphaRI and 83/144 (58%) of the control group (p=0.04). Control tumors were larger (14.3 mm) than those in 5alphaRI treated patients (9.4 mm, p=0.0007). No differences in mean PSA or PSA kinetics were detected between groups. For tumors less than 1.0 cm, the proportion of high grade cancers (Gleason 7-10 and Gleason 4+3-10) was higher in 5alphaRI subjects than in controls (p<0.05). Fewer 5alphaRI patients had proven extracapsular extension than controls, but this difference did not reach statistical significance (p=0.13). Normal DNA ploidy was more likely to be diagnosed in the 5alphaRI group versus controls, but this difference was not statistically significant (81% vs. 65%, p=0.14).

Conclusions: Cancers diagnosed in patients presenting "for cause" treated with 5alphaRI drugs are more likely to be de-differentiated compared to controls. However, these tumors are also smaller and less likely to have extracapsular extension and abnormal DNA ploidy than controls.

 

[Michael Scally MD]

Miller AB. New Data on Prostate-Cancer Mortality after PSA Screening. New England Journal of Medicine 2012;366(11):1047-8. MMS: Error


Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-Cancer Mortality at 11 Years of Follow-up. New England Journal of Medicine 2012;366(11):981-90. MMS: Error

BACKGROUND - Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up.

METHODS - The study involved 182,160 men between the ages of 50 and 74 years at entry, with a predefined core age group of 162,388 men 55 to 69 years of age. The trial was conducted in eight European countries. Men who were randomly assigned to the screening group were offered PSA-based screening, whereas those in the control group were not offered such screening. The primary outcome was mortality from prostate cancer.

RESULTS - After a median follow-up of 11 years in the core age group, the relative reduction in the risk of death from prostate cancer in the screening group was 21% (rate ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.001), and 29% after adjustment for noncompliance. The absolute reduction in mortality in the screening group was 0.10 deaths per 1000 person-years or 1.07 deaths per 1000 men who underwent randomization. The rate ratio for death from prostate cancer during follow-up years 10 and 11 was 0.62 (95% CI, 0.45 to 0.85; P=0.003). To prevent one death from prostate cancer at 11 years of follow-up, 1055 men would need to be invited for screening and 37 cancers would need to be detected. There was no significant between-group difference in all-cause mortality.

CONCLUSIONS - Analyses after 2 additional years of follow-up consolidated our previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.

 

[Michael Scally MD]

Dahabreh IJ, Chung M, Balk EM, et al. Active Surveillance in Men With Localized Prostate Cancer: A Systematic Review. Ann Intern Med. Active Surveillance in Men With Localized Prostate Cancer

Background: Active surveillance (AS) and watchful waiting (WW) have been proposed as management strategies for low-risk, localized prostate cancer.

Purpose: To systematically review strategies for observational management of prostate cancer (AS or WW), factors affecting their utilization, and comparative effectiveness of observational management versus immediate treatment with curative intent.

Data Sources: MEDLINE and Cochrane databases (from inception to August 2011). Study Selection: Screened abstracts and reviewed full-text publications to identify eligible studies.

Data Extraction: One reviewer extracted data, and another verified quantitative data. Two independent reviewers rated study quality and strength of evidence for comparative effectiveness.

Data Synthesis: Sixteen independent cohorts defined AS, 42 studies evaluated factors that affect the use of observational strategies, and 2 evidence reports and 22 recent studies reported comparisons of WW versus treatment with curative intent. The most common eligibility criteria for AS were tumor stage (all cohorts), Gleason score (12 cohorts), prostate-specific antigen (PSA) concentration (10 cohorts), and number of biopsy cores positive for cancer (8 cohorts). For monitoring, studies used combinations of periodic PSA testing (all cohorts), digital rectal examination (14 cohorts), and rebiopsy (14 cohorts). Predictors of receiving no active treatment included older age, comorbid conditions, lower Gleason score, tumor stage, PSA concentration, and favorable risk group. No published studies compared AS with immediate treatment with curative intent. Watchful waiting was generally less effective than treatment with curative intent; however, applicability to contemporary patients may be limited.

Limitations: Active surveillance and WW often could not be differentiated in the reviewed studies. Published randomized trials have assessed only WW and did not enroll patients diagnosed by PSA screening.

Conclusion: Evidence is insufficient to assess whether AS is an appropriate option for men with localized prostate cancer. A standard definition of AS that clearly distinguishes it from WW is needed to clarify scientific discourse. Primary Funding Source: Agency for Healthcare Research and Quality.

 

[Michael Scally MD]

Prebiopsy Magnetic Resonance Spectroscopy And Imaging In The Diagnosis Of Prostate Cancer

Despite its limitations, serum PSA is widely used for screening, early detection, staging and follow up of prostate cancer. The diagnosis of prostate cancer is based on systematic TRUS-guided 6–18 core needle biopsies. In current clinical practice, ultrasound-guided prostate biopsy is recommended for men who have abnormal DRE (regardless of PSA level) and/or elevated PSA level. A PSA level of less than 4 ng/mL is generally accepted in normal limits; however, cancer might be detected in as many as 15% of men with a PSA level less than 4 ng/mL. Recent AUA guidelines recommend obtaining baseline PSA for men aged 40 years and older with a minimum 10-year life expectancy, and do not recommend the use of a single threshold value of PSA to prompt a biopsy of the prostate.

PSA is not specific to prostate cancer, and might be elevated due to other conditions resulting in unnecessary biopsies, especially in patients having PSA 4–10 ng/mL. The biopsy procedure is invasive and might suffer from sampling errors. Therefore, there is a need for a non-invasive diagnostic method with high sensitivity and specificity.

Imaging methods might have the potential to address some of these problems in prostate cancer assessment and management. MRI is at the forefront of the imaging modalities available and has shown potential in prostate cancer imaging. This is a result of the extraordinary capability of MRI to provide anatomical, metabolic and physiological information non-invasively in vivo. Various MR methods are used for obtaining anatomical and functional information. Anatomical/structural information is obtained with the use of T2WI, whereas the metabolic and functional state is obtained using 1H MRS, DWI and DCE-MRI. Recently, MTI has also been explored in prostate cancer. These MR methods, alone or in combination, have been shown to have a potential role in prostate cancer evaluation; for example, detection of prostate cancer, localization, tumor volume, staging, guiding targeted biopsy, tumor aggressiveness and radiation or focal therapy planning.

In the present review, researchers describe the potential role of prebiopsy MR investigations of the prostate. First, a brief description of various MR methods used for prostate cancer evaluation is provided, followed by discussion of clinical applications of prebiopsy MR investigations.


Kumar V, Jagannathan NR, Thulkar S, Kumar R. Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer. International Journal of Urology. Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer - Kumar - 2012 - International Journal of Urology - Wiley Online Library

Introduction: Existing screening investigations for the diagnosis of early prostate cancer lack specificity, resulting in a high negative biopsy rate. There is increasing interest in the use of various magnetic resonance methods for improving the yield of transrectal ultrasound-guided biopsies of the prostate in men suspected to have prostate cancer. We review the existing status of such investigations.

Methods: A literature search was carried out using the Pubmed database to identify articles related to magnetic resonance methods for diagnosing prostate cancer. References from these articles were also extracted and reviewed.

Results: Recent studies have focused on prebiopsy magnetic resonance investigations using conventional magnetic resonance imaging, dynamic contrast enhanced magnetic resonance imaging, diffusion weighted magnetic resonance imaging, magnetization transfer imaging and magnetic resonance spectroscopy of the prostate. This marks a shift from the earlier strategy of carrying out postbiopsy magnetic resonance investigations. Prebiopsy magnetic resonance investigations has been useful in identifying patients who are more likely to have a biopsy positive for malignancy.

Conclusions: Prebiopsy magnetic resonance investigations has a potential role in increasing specificity of screening for early prostate cancer. It has a role in the targeting of biopsy sites, avoiding unnecessary biopsies and predicting the outcome of biopsies.

 

[BBC3]

I would like to know what the data looks like on younger men 35-40 who are diagnosed, and how that compares to you 60 year old - with consideration for the subjects physical conditions and histories... What type PC are the getting mostly. It perhiperal on which side... ? Their hormonal profiles at the time of diagnosis...

 

[Michael Scally MD]

Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D3 Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer under Active Surveillance. Journal of Clinical Endocrinology & Metabolism. Vitamin D3 Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer under Active Surveillance

Context: We wanted to investigate vitamin D in low-risk prostate cancer.

Objectives: The objective of the study was to determine whether vitamin D3 supplementation at 4000 IU/d for 1 yr is safe and would result in a decrease in serum levels of prostate-specific antigen (PSA) or in the rate of progression.

Design: In this open-label clinical trial (Investigational New Drug 77,839), subjects were followed up until repeat biopsy.

Setting: All subjects were enrolled through the Medical University of South Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, both in Charleston, SC.

Patients and Other Participants: All subjects had a diagnosis of low-risk prostate cancer. Fifty-two subjects were enrolled in the study, 48 completed 1 yr of supplementation, and 44 could be analyzed for both safety and efficacy objectives.

Intervention: The intervention included vitamin D3 soft gels (4000 IU).

Main Outcome Measures: Adverse events were monitored throughout the study. PSA serum levels were measured at entry and every 2 months for 1 yr. Biopsy procedures were performed before enrollment (for eligibility) and after 1 yr of supplementation.

Results: No adverse events associated with vitamin D3 supplementation were observed. No significant changes in PSA levels were observed. However, 24 of 44 subjects (55%) showed a decrease in the number of positive cores or decrease in Gleason score; five subjects (11%) showed no change; 15 subjects (34%) showed an increase in the number of positive cores or Gleason score.

Conclusion: Patients with low-risk prostate cancer under active surveillance may benefit from vitamin D3 supplementation at 4000 IU/d.

 

[Flav]

Is there anything vitamin d doesn't do?!

 

[HeadDoc]

http://www.telegraph.co.uk/health/healthnews/9206425/New-treatment-for-prostate-cancer-gives-perfect-results-for-nine-in-ten-men-research.html

treatment is just about side effect free.

 

[Michael Scally MD]

http://www.telegraph.co.uk/health/healthnews/9206425/New-treatment-for-prostate-cancer-gives-perfect-results-for-nine-in-ten-men-research.html

treatment is just about side effect free.

Uchida T, Nakano M, Hongo S, et al. High-intensity focused ultrasound therapy for prostate cancer. International Journal of Urology 2012;19(3):187-201. High-intensity focused ultrasound therapy for prostate cancer - Uchida - 2011 - International Journal of Urology - Wiley Online Library

Recent advances in high-intensity focused ultrasound, which was developed in the 1940s as a viable thermal tissue ablation approach, have increased its popularity. High-intensity focused ultrasound is currently utilized the most in Europe and Japan, but has not yet been approved by the Food and Drug Administration, USA, for this indication. The purpose of the present report is to review the scientific foundation of high-intensity focused ultrasound technology and the clinical outcomes achieved with commercially available devices. Recently published articles were reviewed to evaluate the current status of high-intensity focused ultrasound as a primary or salvage treatment option for localized prostate cancer. Improvements in the clinical outcome as a result of technical, imaging and technological advancements are described herein. A wide range of treatment options for organ-confined prostate cancer is available. However, high-intensity focused ultrasound is an attractive choice for men willing to choose less invasive options, although establishing the efficacy of high-intensity focused ultrasound requires longer follow-up periods. Technological advances, together with cultural and economic factors, have caused a dramatic shift from traditional open, radical prostatectomy to minimally invasive techniques. High-intensity focused ultrasound is likely to play a significant role in the future of oncology practice.

 

[BBC3]

Man, Looking back I appear to be like some little cricket chirping outside the window. LOL... But I'm tryin...

Oh yea, the reason for this post was that the other day I learned that a fellow I have met a few times "had his entire prostate removed". This was the quote from a poor source. But the point is that I THINK I gathered he has/had prostate cancer - AND BEFORE THE AGE OF 40........!!!!! I will try to gather more, but from what I recall the only vices he had/has were drinking (very excessively), smoking, and an incredible love for vagina. I also gather he could have probably stroked himself senseless if he never had to go to work. Seriously...

And no discount. It is a tragedy as in anyone stricken with this. I wish him only the best. So I will try to gather more to make sense of it....

 

[Michael Scally MD]

BREAKING: WARREN BUFFETT DIAGNOSED WITH STAGE 1 PROSTATE CANCER

Read more: Warren Buffett Diagnosed With Stage 1 Prostate Cancer - Business Insider

BERKSHIRE HATHAWAY INC. NEWS RELEASE FOR IMMEDIATE RELEASE April 17, 2012
Omaha, NE (BRK.A; BRK.B) –

To the Shareholders of Berkshire Hathaway:

This is to let you know that I have been diagnosed with stage I prostate cancer.

The good news is that I’ve been told by my doctors that my condition is not remotely life- threatening or even debilitating in any meaningful way. I received my diagnosis last Wednesday. I then had a CAT scan and a bone scan on Thursday, followed by an MRI today. These tests showed no incidence of cancer elsewhere in my body.

My doctors and I have decided on a two-month treatment of daily radiation to begin in mid-July. This regimen will restrict my travel during that period, but will not otherwise change my daily routine.

I feel great – as if I were in my normal excellent health – and my energy level is 100 percent. I discovered the cancer because my PSA level (an indicator my doctors had regularly checked for many years) recently jumped beyond its normal elevation and a biopsy seemed warranted.

I will let shareholders know immediately should my health situation change. Eventually, of course, it will; but I believe that day is a long way off.

 

[BBC3]

Sadly, this may only prove in fact that all PSA count is for with regard to PC is to determine when the $realwheel$ start churning. Yes so a PSA elevates when there is a physical disruption in the prostate. Doesn't that mean it's ALREADY too late!!! Well at least we will now get to see what kind of treatment real money gets, and what the optimal prognosis in optimal treatment conditions is. But I don't think I read exactly what type he has, and what his history with digital exams is?? I will look again. One thing is for sure is that he is a man of thorough edication prior to sound action. The question is, will he share his findings to any degree beyond the normal bait for SUPPORT he is accustomed to....